Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs AdaptHealth Corp (AHCO) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
AdaptHealth CorpTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs AdaptHealth Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while AdaptHealth Corp trades at $5.75 (market cap $753.09M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 6.7× AdaptHealth Corp's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, AdaptHealth Corp nearer its low. Which is the better fit depends on your goals.

ACADAHCO
Market Cap
$5.07B$753.09M
Sector
HealthHealth
52-Week High
$29.41$13.38
52-Week Low
$20.06$5.22
Enterprise Value
$4.19B$2.77B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.

AdaptHealth Corp

AdaptHealth (AHCO) trades at $5.77, up 10.54% today but remains under significant pressure following recent earnings disappointments. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal revenue growth but negative profitability margins. Recent news highlights multiple securities fraud investigations and a strategic shift through the sale of its diabetes unit to focus on sleep and respiratory care.

Despite 75% analyst buy ratings and an $11 consensus price target suggesting substantial upside, immediate risks are elevated. The company faces execution challenges with fixed-price contracts, ongoing legal scrutiny, and consecutive earnings misses. Investors must weigh the potential recovery against substantial operational and legal headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About AdaptHealth Corp

AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.

Read more on AHCO